13. Department of Safety Research on
Blood and Biological Products

R, Matsumoto C, Kaneko N, Tezuka K, Matsuoka S,
Utsunomiya A, Koh KR, Ogata M, Ishitsuka K, Taki M,
Nosaka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano1）Kusunoki H, Tanaka T, Kohno T, Matsuhashi K, Hosoda

Y, Okayama A, Miura K, Satake M, Saito S, Watanabe T,

K, Wakamatsu K, Hamaguchi I. A novel neuropilin-1

Hamaguchi I. Development of reference material with-binding sequence in the human T-cell lymphotropic

assigned value for human T-cell leukemia virus type 1

virus type 1 envelope glycoprotein, BBA, 2018, 1866(4),quantitative PCR in Japan. Microbiol Immunol. 2018541-548.

Oct;62(10):673-676.

2）Sasaki E, Momose H, Hiradate Y, Furuhata K, Mizukami8 ） Momose H, Sasaki E, Kuramitsu M, Hamaguchi I,

T, Hamaguchi I. Development a preclinical model to

Mizukami T, Gene expression profiling toward the next

evaluate

generation safety control of influenza vaccines andinfluenzavaccineacute

toxicityusinghumanized mouse model. Oncotarget. 2018, 9(40):25751-25763.

adjuvants in Japan. Vaccine, 2018. 36:6449-6455.
9 ） Sasaki E, Momose H, Hiradate Y, Mizukami T,

3）Fukumoto T, Ikebe E, Ogata M, Kohno K, Kuramitsu M,

Hamaguchi I. Establishment of a novel safety assessment

Sato Y, Fife N, Matsumoto T, Yahiro T, Ikeda M, Kusano

method for vaccine adjuvant development. Vaccine. 2018,

S, Okayama A, Hori M, Hijiya N, Tsukamoto Y, Hirashita

36(46): 7112-7118.

Y, Moriyama M, Ahmed K, Hasegawa H, Nishizono A,

10）Sasaki E, Momose H, Hiradate Y, Ishii KJ, Mizukami T,

Saito M, Iha H. Complete Sequences of the Human

Hamaguchi I. In vitro marker gene expression analyses in

T-Cell Leukemia Virus Type 1 Proviral Genomes fromhuman peripheral blood mononuclear cells: A tool to

Newly Established Adult T-Cell Leukemia Cell Lines inassess safety of influenza vaccines in humans. J

Oita Prefecture, Japan.

Immunotoxicol. 2018, 15(1): 53-62.

Genome Announc.

2018;

21;6(25).

11 ） Sasaki E, Mizukami T, Hamaguchi I. 「 Influenza

4）Momose H, Matsuoka S, Murayama A, Yamada N,

Therapeutics and Challenges」2018, p113-p130 Genomic

Okuma K, Ikebe E, Hoshi Y, Muramatsu M, Wakita T,

Approaches Enable Evaluation of the Safety and Quality

Toyota K, Kato T, Hamaguchi I. Evaluation of in vitroof Influenza Vaccines and Adjuvants. InTech ISBN:

screening and diagnostic kits for hepatitis C virus

978-1-78923-715-3.

infection. J Clin Virol. 2018 Aug;105:97-102.

12 ） Kamoi K, Okayama A, Izumo S, Hamaguchi I,

5） Toki T, Yoshida K, Wang R, Nakamura S, Maekawa T,

Uchimaru K, Tojo A,Ohno-Matsui K, Adult T-cell

Goi K, Katoh MC, Mizuno S, Sugiyama F, Kanezaki R,

leukemia/lymphoma-related

ocularmanifestations:Uechi T, Nakajima Y, Sato Y, Okuno Y, Sato-Otsubo A,

analysis of the first large-scale nationwide survey, 2019,

Shiozawa Y, Kataoka K, Shiraishi Y, Sanada M, Chiba K,

Front Microbiol, 8;9:3240.

Tanaka H, Terui K, Sato T, Kamio T, Sakaguchi H, Ohga

13）Ikebe E, Matsuoka S, Tanaka A, Yonemura Y, Fujii Y,

S, Kuramitsu M, Hamaguchi I, Ohara A, Kanno H,

Ohsaka A, Okazaki H, Kitazawa J, Ohtani S, Nakayama

Miyano S, Kojima S, Ishiguro A, Sugita K, Kenmochi N,

T, Momose SY, Miwa I, Taira R, Toyota K, Kino S, Kato

Takahasi S, Eto K, Ogawa S, Ito E. De novo mutations

H, Hamaguchi I. Reduction in adverse transfusion

activating germline TP53 in an inherited bone marrow

reactionsfailureconcentrates in Japan-A retrospective multicenter study.

syndrome.

Am

J

Hum

Genet.

2018.

103(3):440-447.

withincreased

useofwashedplateletTransfus Apher Sci. In press.

6）Hiradate Y, Sasaki E, Momose H, Asanuma H, Furuhata

14 ） Murayama A, Momose H, Yamada N, Hoshi Y,

K, Takai M, Aoshi T, Yamada H, Ishii KJ, Tanemura K,

Muramatsu M, Wakita T, Ken Ishimaru K,Hamaguchi I,

Mizukami T, Hamaguchi I. Development of screening

Kato T, Evaluation of In Vitro Screening and Diagnostic

method for intranasal influenza vaccine and adjuvant

Kits for Hepatitis B Virus Infection, 2019, J Clinc Virol,

safety in preclinical study. Biologicals. 2018; 55: 43-52.

In press.

7）Kuramitsu M, Okuma K, Nakashima M, Sato T, Sasaki

15）Noyori O, Komohara Y, Nasser H, Hiyoshi M, Ma C,

D, Hasegawa H, Umeki K, Kubota R, Sasada K, Sobata

Pan C, Carreras J, Nakamura N, Sato A, Ando K, Okuno

Y, Nosaka K, Matsuoka M, Suzu S. Expression of IL-34
correlates with macrophage infiltration and prognosis ofdiffuse large B cell lymphoma. Clin Transl Immunology,
In press.
16）Tateishi K, Fujihashi K, Yamamoto N, Hasegawa H,
Ainai A, Sato K, Iho S, Yamamoto S, Maeyama J,
Odagiri T, Asanuma H. CpG ODN G9.1 as a novel nasal
ODN adjuvant elicits complete protection from influenza
virus infection without causing inflammatory immune
responses, Vaccine. In press.
17）Kusunoki H, Tanaka T, Kohno T, Kimura H, Hosoda
K, Wakamatsu K, Hamaguchi I, NMR characterization of
the interaction between Bcl-x L and the BH3-like motif ofhepatitis B virus X protein, Biochem Biophys Res Comm,
In press.
18 ） Kuramitsu M, Okuma K, Tezuka K, Nakamura H,
Sagara Y, Kurane I, Hamaguchi I, Development andevaluation of human T-cell leukemia virus-1 and -2
multiplex quantitative PCR, Microbiol. Immunol. In
press.